Three reasons for the increase in Q2 EBITDA and PAT are as follows:
oncology sales outsourced
soft gel sales increase
reasonable increase in the revenue of Caplin Steriles
Growth drivers for the next three years:
In the financial year 2023-2024 outsourcing of onco business has continued to contribute revenue and profits
CSL line 5 which is a new line that increased the capacity
the new registration of soft gels will also contribute to the top and bottom line of our current financial year
They are sure to maintain current metrics such as EBITDA and PAT in the financial year 2023-2024.
FY 2024-2025 plans:
CSL line 5 and line 6 will contribute to company growth
increased ANDAs
replacement of line one with a high-speed lines
Completion of onco OSD such as tablet and capsule will also increase the revenue
FY 2025-2026 plans:
Expect completion of onco injectables in addition to OSD to expand OSD general facilities for the new markets
New and larger geographies of various countries such as Mexico and others where the increase in registration will also contribute to company growth
Expansions such as API in Vizag, Onco facility in Kakkalur, Thiruvallur, and the new OSD general facility in Gummidipoondi and line 6 in CSL will be completed between 12 to 18 months without fail
goods next to the customer and the warehouse have created a new ecosystem for preventing supply chain challenges
| Subscribe To Our Free Newsletter |
